Emmaus Life Sciences, Inc. EMMA 0.26 Emmaus Life Sciences, Inc.

Home
⇒ 
Stock List ⇒ Emmaus Life Sciences, Inc.
Range:1.0E-4-0.17Vol Avg:37971Last Div:0Changes:0.01
Beta:6.35Cap:0.00BCurrency:USDExchange:PNK
Sector:HealthcareIPO:Tue May 09 2000Empoloyees:51
CUSIP:29137T101CIK:0000822370ISIN:US29137T1016Country:US
CEO:Mr. Willis C. Lee M.S.Website:https://www.emmausmedical.com
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection StatusPowered by StackThrow